3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:百万円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 15,439 | 15,132 |
受取手形 | 69 | 51 |
売掛金 | 8,172 | 7,192 |
有価証券 | 5,592 | 3,592 |
商品及び製品 | 3,201 | 3,398 |
仕掛品 | 3,120 | 3,893 |
原材料及び貯蔵品 | 3,025 | 2,906 |
その他 | 2,953 | 3,516 |
貸倒引当金 | △27 | △53 |
流動資産合計 | 41,546 | 39,631 |
固定資産 | | |
有形固定資産 | | |
建物及び構築物 | 21,221 | 22,183 |
減価償却累計額 | △15,476 | △16,049 |
建物及び構築物(純額) | 5,744 | 6,133 |
機械装置及び運搬具 | 24,624 | 26,101 |
減価償却累計額 | △21,180 | △22,042 |
機械装置及び運搬具(純額) | 3,444 | 4,058 |
土地 | 1,106 | 1,123 |
リース資産 | 147 | 144 |
減価償却累計額 | △64 | △77 |
リース資産(純額) | 82 | 67 |
建設仮勘定 | 3,728 | 5,818 |
その他 | 6,203 | 6,564 |
減価償却累計額 | △5,091 | △5,314 |
その他(純額) | 1,111 | 1,250 |
有形固定資産合計 | 15,219 | 18,452 |
無形固定資産 | | |
のれん | 2,107 | 1,965 |
その他 | 1,093 | 1,184 |
無形固定資産合計 | 3,200 | 3,149 |
投資その他の資産 | | |
投資有価証券 | 18,790 | 19,038 |
退職給付に係る資産 | 1,768 | 2,296 |
その他 | 1,276 | 1,311 |
貸倒引当金 | △7 | △7 |
投資その他の資産合計 | 21,828 | 22,639 |
固定資産合計 | 40,248 | 44,241 |
資産合計 | 81,795 | 83,872 |
| | (単位:百万円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
負債の部 | | |
流動負債 | | |
買掛金 | 1,652 | 991 |
短期借入金 | 300 | 300 |
リース債務 | 35 | 33 |
未払金 | 2,851 | 3,729 |
未払法人税等 | 113 | 106 |
賞与引当金 | 676 | 829 |
環境対策引当金 | 124 | 108 |
その他 | 1,443 | 1,800 |
流動負債合計 | 7,198 | 7,899 |
固定負債 | | |
リース債務 | 61 | 47 |
繰延税金負債 | 2,108 | 2,594 |
資産除去債務 | 37 | 38 |
その他 | 106 | 106 |
固定負債合計 | 2,313 | 2,786 |
負債合計 | 9,512 | 10,685 |
純資産の部 | | |
株主資本 | | |
資本金 | 3,840 | 3,840 |
資本剰余金 | 5,301 | 5,301 |
利益剰余金 | 54,738 | 54,422 |
自己株式 | △2,259 | △2,242 |
株主資本合計 | 61,620 | 61,322 |
その他の包括利益累計額 | | |
その他有価証券評価差額金 | 5,526 | 5,072 |
為替換算調整勘定 | 4,180 | 5,643 |
退職給付に係る調整累計額 | 954 | 1,148 |
その他の包括利益累計額合計 | 10,661 | 11,864 |
純資産合計 | 72,282 | 73,187 |
負債純資産合計 | 81,795 | 83,872 |
E0097045480生化学工業株式会社SEIKAGAKU CORPORATION通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2024-04-012025-03-31FY2025-03-312023-04-012024-03-312024-03-311falsefalsefalse454802025-03-31jppfs_cor:CapitalSurplusMember454802025-03-31jppfs_cor:RetainedEarningsMember454802025-03-31jppfs_cor:TreasuryStockMember454802025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember454802025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember454802025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember454802024-04-012025-03-31jppfs_cor:ShareholdersEquityMember454802024-04-012025-03-31jppfs_cor:CapitalStockMember454802024-04-012025-03-31jppfs_cor:CapitalSurplusMember454802024-04-012025-03-31jppfs_cor:RetainedEarningsMember454802024-04-012025-03-31jppfs_cor:TreasuryStockMember454802024-04-012025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember454802024-04-012025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember454802024-04-012025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember454802023-03-31jppfs_cor:CapitalSurplusMember454802023-03-31jppfs_cor:RetainedEarningsMember454802023-03-31jppfs_cor:TreasuryStockMember454802023-03-31jppfs_cor:ShareholdersEquityMember454802023-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember454802023-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember454802023-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember454802023-04-012024-03-31jppfs_cor:CapitalSurplusMember454802023-04-012024-03-31jppfs_cor:RetainedEarningsMember454802023-04-012024-03-31jppfs_cor:TreasuryStockMember454802023-04-012024-03-31jppfs_cor:ShareholdersEquityMember454802024-03-31jppfs_cor:CapitalStockMember454802025-03-31jppfs_cor:CapitalStockMember454802025-03-31jppfs_cor:DeferredGainsOrLossesOnHedgesMember454802024-04-012025-03-31jppfs_cor:DeferredGainsOrLossesOnHedgesMember454802024-03-31jppfs_cor:DeferredGainsOrLossesOnHedgesMember454802023-04-012024-03-31jppfs_cor:DeferredGainsOrLossesOnHedgesMember454802023-03-31jppfs_cor:DeferredGainsOrLossesOnHedgesMember454802024-04-012025-03-31454802024-03-31454802023-04-012024-03-31454802025-05-13454802023-03-31454802025-03-31454802023-04-012024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember454802023-04-012024-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember454802023-04-012024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember454802023-04-012024-03-31jppfs_cor:CapitalStockMember454802024-03-31jppfs_cor:CapitalSurplusMember454802024-03-31jppfs_cor:RetainedEarningsMember454802024-03-31jppfs_cor:TreasuryStockMember454802024-03-31jppfs_cor:ShareholdersEquityMember454802024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember454802024-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember454802024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember454802023-03-31jppfs_cor:CapitalStockMember454802023-04-012024-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember454802023-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember454802025-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember454802024-04-012025-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember454802024-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember454802025-03-31jppfs_cor:ShareholdersEquityMember454802024-04-012025-03-31jpcrp_cor:ReportableSegmentsMember454802024-03-31jpcrp_cor:ReportableSegmentsMember454802023-04-012024-03-31jpcrp_cor:ReportableSegmentsMember454802025-03-31jpcrp_cor:ReportableSegmentsMember454802024-04-012025-03-31tse-acedjpfr-45480:PharmaceuticalReportableSegmentsMember454802024-04-012025-03-31tse-acedjpfr-45480:LALReportableSegmentsMember454802024-03-31tse-acedjpfr-45480:PharmaceuticalReportableSegmentsMember454802024-03-31tse-acedjpfr-45480:LALReportableSegmentsMember454802023-04-012024-03-31tse-acedjpfr-45480:PharmaceuticalReportableSegmentsMember454802023-04-012024-03-31tse-acedjpfr-45480:LALReportableSegmentsMember454802025-03-31tse-acedjpfr-45480:PharmaceuticalReportableSegmentsMember454802025-03-31tse-acedjpfr-45480:LALReportableSegmentsMember454802024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember454802024-03-31jpcrp_cor:ReconcilingItemsMember454802023-04-012024-03-31jpcrp_cor:ReconcilingItemsMember454802025-03-31jpcrp_cor:ReconcilingItemsMemberxbrli:pureiso4217:JPY